Treatment Options for H5N1: Lessons Learned from the H1N1 Pandemic

References

• . World Health Organization. H5N1 avian influenza: timeline of major events. http://www.who.int/csr/disease/avian_influenza/Time-line090727.pdf. Accessed July 1, 2010
   Google Scholar
• . World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_07_05/en/index.html. Accessed July 10, 2010
   Google Scholar
• . Lebarbenchon C, Feare CJ, Renaud F, . Persistence of highly pathogenic avian influenza viruses in natural ecosystems. Emerg Infect Dis. 2010;16(7):1057–1062
   Google Scholar
• . World Health Organization. Ten concerns if avian influenza becomes a pandemic. October 14, 2005. http://www.who.int/csr/disease/influenza/pandemic10things/en/index.html. Accessed July 2, 2010
   Google Scholar
• . McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis. 2007;13(9):1354–1357
   Google Scholar
• . Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/HongKoηg/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. JInfect Dis. 1998;178(6):1592–1596
   Google Scholar
• . Reece PA. Zanamivir for the treatment of avian influenza infections in humans. Expert Rev Clin Pharmacol. 2010;3(1):25–29
   PubMedGoogle Scholar
• . Loeffelholz MJ. Avian influenza A H5N1 virus. Clin Lab Med. 2010;30(1):1–20
   Google Scholar
• . World Health Organization. Avian influenza (“bird flu”). http://www.who.int/mediacentre/factsheets/avian_influenza/en/. Accessed July 2, 2010
   Google Scholar
• . Korteweg C, Gu J. Pandemic influenza A (H1N1) virus infection and avian influenza A (H5N1) virus infection: a comparative analysis. Biochem Cell Biol. 2010;88(4):575–587
   Google Scholar
• . Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, . Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis. 2005;11(2):201–209
   Google Scholar
• . Smith JR. Oseltamivir in human avian influenza infection. J Antimicrob Chemother. 2010;65( suppl 2):ii25–ii33
   PubMed Web of Science ®Google Scholar
• . Soepandi PZ, Burhan E, Mangunnegoro H, ; the H5N1 Clinical Team.Clinical course of H5N1 avian influenza in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005–2008 [published online ahead of print May 27, 2010]. Chest.
   Google Scholar
• . Fasina FO, Ifende VI, Ajibade AA. Avian influenza A (H5N1) in humans: lessons from Egypt. Euro Surveill. 2010;15(4):19473
   Google Scholar
• . Kandeel A, Manoncourt S, Abd el Kareem E, . Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006–2009. Emerg Infect Dis. 2010;16(7):1101–1107
   Google Scholar
• . Taylor WR, Burhan E, Wertheim H, . Avian influenza—a review for doctors in travel medicine. Travel Med Infect Dis. 2010;8(1):1–12
   Google Scholar
• . Sambhara S, Poland GA. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Ann Rev Med. 2010;61:187–198
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. Updated August 15, 2007. http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf. Accessed July 3, 2010
   Google Scholar
• . Rameix-Welti MA, Agou F, Buchy P, . Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother. 2006;50(11):3809–3815
   Google Scholar
• . Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007;73(3):228–231
   Google Scholar
• . de Jong MD, Tran TT, Truong HK, . Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353(25):2667–2672
   PubMed Web of Science ®Google Scholar
• . Boltz DA, Douangngeun B, Phommachanh P, . Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol. 2010;91(pt 4):949–959
   PubMed Web of Science ®Google Scholar
• . Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model [published online ahead of print June 2, 2010]. J Virol.
   Google Scholar
• . Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 2010;6(5):e1000933
   Google Scholar
• . Ujike M, Shimabukuro K, Mochizuki K, ; Working Group for Influenza Virus Surveillance in Japan. Oseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons. Japan Emerg Infect Dis. 2010;16(6):926–935
   Google Scholar
• . World Health Organization. Influenza A (H1N1) virus resistance to oseltamivir—2008/2009 influenza season, northern hemisphere. March 18, 2009. http://www.who.int/csr/disease/influenzA(H1N1)webupdate20090318%20ed_ns.pdf. Accessed July 3, 2010
   Google Scholar
• . Matsuzaki Y, Mizuta K, Aoki Y, . A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J. 2010;7:53
   Google Scholar
• . Baranovich T, Saito R, Suzuki Y, ; Japanese Influenza Collaborative Study Group. Emergence of H275Y oseltamivir-resistant A (H1N1) influenza viruses in Japan during the 2008–2009 season. J Clin Virol. 2010;47(1):23–28
   Google Scholar
• . Kawai N, Ikematsu H, Hirotsu N, . Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H275Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. Clin Infect Dis. 2009;49(12):1828–1835
   Google Scholar
• . Sy CL, Lee SS, Liu MT, Tsai HC, Chen YS. Rapid emergence of oseltamivir resistance. Emerg Infect Dis. 2010;16(4):723–725
   Google Scholar
• . World Health Organization. World Health Organization. Pandemic (H1N1) 2009—update 108. Weekly update. July 9, 2010. http://www.who.int/csr/don/2010_07_09/en/index.html. Accessed July 10, 2010
   Google Scholar
• . World Health Organization. Weekly update on oseltamivir resistance to pandemic influenza A (H1N1) 2009 viruses. June 9, 2010. http://www.who.int/csr/disease/swineflu/oseltamivirresistant20100611.pdf. Accessed July 3, 2010
   Google Scholar
• . Janies DA, Voronkin IO, Studer J, . Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages. Int J Health Geogr. 2010;9:13
   Web of Science ®Google Scholar
• . Zonis Z, Engelhard D, Hindiyeh M, . Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. Emerg Infect Dis. 2010;16(6):1045–1046
   Google Scholar
• . Tramontana AR, George B, Hurt AC, . Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. Emerg Infect Dis. 2010;16(7):1068–1075
   PubMedGoogle Scholar
• . Baz M, Abed Y, Simon P, . Effect of the neuraminidase mutation H275Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A (H1N1) viruses. J Infect Dis. 2010;201(5):740–745
   PubMedGoogle Scholar
• . Esposito S, Molteni CG, Colombo C, . Oseltamivir-induced resistant pandemic A (H1N1) influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol. 2010;48(1):62–65
   Google Scholar
• . Wang B, Dwyer DE, Blyth CC, . Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A (H1N1) 09 infections. Antiviral Res. 2010;87(1):16–21
   PubMedGoogle Scholar
• . Glikman D, Zonis Z, Hindyieh M, . Development of oseltamivir resistance during oseltamivir therapy in a child with severe 2009 H1N1 influenza. Pediatr Infect Dis J. 2010;29(4):385–386
   PubMed Web of Science ®Google Scholar
• . Speers DJ, Williams SH, Pinder M, Moody HR, Hurt AC, Smith DW. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust. 2010;192(3):166–168
   PubMedGoogle Scholar
• . Harvala H, Gunson R, Simmonds P, . The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. Euro Surveill. 2010;15(14):19536
   Google Scholar
• . Health Protection Agency. Inpatient clinical management issues relating to oseltamivir-resistant pandemic (H1N1) 2009 influenza virus. Version 2, 2010. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259152289698. Accessed July 3, 2010
   Google Scholar
• . World Health Organization. Oseltamivir resistance in immunocompromised hospital patients. Pandemic (H1N1) 2009 briefing note 18. http://www.who.int/csr/disease/swineflu/notes/briefing_20091202/en/index.html. Accessed July 3, 2010
   Google Scholar
• . Mandelboim M, Hindiyeh M, Meningher T, Mendelson E. Possible transmission of pandemic (HIN1) 2009 virus with oseltamivir resistance. Emerg Infect Dis. 2010;16(5):873–874
   Google Scholar
• . Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328(5983):1272–1275
   PubMed Web of Science ®Google Scholar
• . Gubareva LV, Fry AM. Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses. J Infect Dis. 2010;201(5):656–658
   Google Scholar
• . Saito R, Sato I, Suzuki Y, . Reduced Effectiveness of Oseltamivir in Children Infected With Oseltamivir-Resistant Influenza A (H1N1) Viruses With His275Tyr Mutation [published online ahead of print May 3, 2010]. Pediatr Infect Dis J.
   Google Scholar
• . Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol. 2007;79(10):1577–1586
   Web of Science ®Google Scholar
• . Nayak JL, Treanor JJ. Antiviral treatment and prophylaxis of influenza virus in children. Pediatr Ann. 2009;38(12):667–674
   Google Scholar
• . Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178(5):1257–1262
   PubMedGoogle Scholar
• . Hurt AC, Lowther S, Middleton D, Barr IG. Assessing the development of oseltamivir and zanamivir resistance in A (H5N1) influenza viruses using a ferret model [published online ahead of print July 2, 2010]. Antiviral Res.
   Google Scholar
• . Zürcher T, Yates PJ, Daly J, . Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. Antimicrob Chemother. 2006;58(4):723–732
   Google Scholar
• . Falagas ME, Vouloumanou EK, Baskouta E, . Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents. 2010;35(5):421–430
   Google Scholar
• . World Health Organization. Oseltamivir resistant pandemic (H1N1) 2009 influenza virus, October 1999. Weekly epidemiological record. http://www.who.int/wer/2009/wer8444.pdf. Accessed July 3, 2010
   Google Scholar
• . Chan PA, Connell NT, Gabonay AM, . Oseltamivir resistant 2009–2010 pandemic influenza A (H1N1) in an immunocompromised patient [March 10, 2010]. Clin Microbiol Infect.
   Google Scholar
• . Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother. 1999;43(7):1616–1620
   PubMed Web of Science ®Google Scholar
• . Stittelaar KJ, Tisdale M, van Amerongen G, . Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res. 2008;80(2):225–228
   Google Scholar
• . Dulek DE, Williams JV, Creech CB, . Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis. 2010;50(11):1493–1496
   Google Scholar
• . Härter G, Zimmermann O, Maier L, . Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis. 2010;50(9):1249–1251
   Google Scholar
• . Gaur AH, Bagga B, Barman S, . Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med. 2010;362(1):88–89
   PubMed Web of Science ®Google Scholar
• . Ison MG, Gnann JW Jr, Nagy-Agren S, ; NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003;8(3):183–190
   PubMed Web of Science ®Google Scholar
• . Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis. 2010;50(4):620
   PubMed Web of Science ®Google Scholar
• . Steel HM, Peppercorn AF. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis. 2010;51(1):121
   Google Scholar
• . Eagel BA. The truth about Tamiflu? Zanamivir should be inhaled, not nebulized. BMJ. 2010;340:c131
   PubMedGoogle Scholar
• . Mancuso CE, Gabay MP, Steinke LM, . Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza (July/August) [published online ahead of print June 1, 2010]. Ann Pharmacother.
   Google Scholar
• . Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361(23):2204–2207
   PubMed Web of Science ®Google Scholar
• . Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drugs Today (Barc). 2010;46(6):399–408
   Google Scholar
• . Memoli MJ, Hrabal RJ, Hassantoufighi A, . Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010;50(9):1252–1255
   PubMed Web of Science ®Google Scholar
• . Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54(6):2575–2582
   PubMed Web of Science ®Google Scholar
• . Kiso M, Kubo S, Ozawa M, . Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010;6(2):e1000786
   Google Scholar